• 1
    Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S5S.
  • 2
    Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am J Hypertens 2011; 24: 86375.
  • 3
    Grossman E. Should we treat prehypertension in diabetes? What are the cons? Diabetes Care 2009; 32(2): S2803.
  • 4
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 10539.
  • 5
    Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 30410.
  • 6
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 190313.
  • 7
    Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The atherosclerosis risk in communities (aric) study investigators. Diabetes Care 1999; 22: 107783.
  • 8
    Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 244752.
  • 9
    Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc 2002; 94: 7S15S.
  • 10
    American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care 2008; 31(1): S1254.
  • 11
    Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 1980; 302: 64550.
  • 12
    Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 103842.
  • 13
    Fogari R, Zoppi A, Malamani GD, Lazzari P, Destro M, Corradi L. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. Am J Hypertens 1993; 6: 17.
  • 14
    Ozawa M, Tamura K, Iwatsubo K, et al. Ambulatory blood pressure variability is increased in diabetic hypertensives. Clin Exp Hypertens 2008; 30: 21324.
  • 15
    Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33: 43441.
  • 16
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: 21329.
  • 17
    American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care 2010; 33(1): S1161.
  • 18
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 256072.
  • 19
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet 1998; 351: 175562.
  • 20
    Grossman E, Goldbourt U. Hypertension optimal treatment (HOT) trial. Lancet 1998; 352: 572; author reply 574-575.
  • 21
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 38. BMJ. 1998; 317: 70313.
  • 22
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000; 321: 4129.
  • 23
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the advance trial): A randomised controlled trial. Lancet 2007; 370: 82940.
  • 24
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). SHEP cooperative research group. JAMA 1991; 265: 325564.
  • 25
    Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985; 1: 134954.
  • 26
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine gits study: intervention as a goal in hypertension treatment (insight). Lancet 2000; 356: 36672.
  • 27
    Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 123745.
  • 28
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the nordic diltiazem (NORDIL) study. Lancet 2000; 356: 35965.
  • 29
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the swedish trial in old patients with hypertension-2 study. Lancet 1999; 354: 17516.
  • 30
    Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPP) randomised trial. Lancet 1999; 353: 6116.
  • 31
    Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in china (syst-china) collaborative group. J Hypertens 1998; 16: 18239.
  • 32
    Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 215772.
  • 33
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in europe (syst-eur) trial investigators. Lancet 1997; 350: 75764.
  • 34
    Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 march 2003. J Hypertens 2003; 21: 105576.
  • 35
    Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 152735.
  • 36
    Grossman E. Blood pressure, the lower, the better: the con side. Diabetes Care 2011; 34(2): S30812.
  • 37
    Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 108697.
  • 38
    Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the hot study with different risk profiles: does a j-shaped curve exist in smokers? J Hypertens 2003; 21: 797804.
  • 39
    Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 122537.
  • 40
    Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 117483.
  • 41
    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 154759.
  • 42
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens 2009; 27: 13609.
  • 43
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 618.
  • 44
    Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 157585.
  • 45
    Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 23344.
  • 46
    Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799810.
  • 47
    Cheng XM, Ziegler DK, Lai YH, et al. Stroke in China, 1986 through 1990. Stroke 1995; 26: 19904.
  • 48
    Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 70716.
  • 49
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.